$29.68
Value $1.7B
AGIO and AMGN stock compared: price, dividend, valuation and results, from SEC filings.
$29.68
Value $1.7B
$443.89
Value $239B
Agios Pharmaceuticals (AGIO) has a market value of $1.7B and Amgen (AMGN) $239B. Over the last year, with dividends, AGIO moved -34.2% and AMGN +33.5%. Dividend yield: AGIO none, AMGN 2.24%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AGIO$1.7B
AMGN$239B
AMGN is 138 times AGIO
Revenue, 12 months
AGIO$141M
AMGN$38.9B
AMGN is 276 times AGIO
Net income, 12 months
AGIO-$373M
AMGN$9.4B
Operating margin
AGIO-297.7%
AMGN32.4%
330.1 points apart
ROIC
AGIO-29.6%
AMGN16.2%
45.8 points apart
P/E
AGIO–
AMGN25.5
Dividend yield
AGIO0.0%
AMGN2.2%
2.2 points apart
5-year return
AGIO-25.2%
AMGN+149.9%
175.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AGIO-25.2%
AMGN+149.9%
| Period | AGIOWith dividends | AMGNWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | -34.2%Price -34.2% | +33.5%Price +29.9% |
| 3 years since November 17, 2023 | +33.3%+10.1% a yearPrice +33.3% | +81.6%+22.0% a yearPrice +67.3% |
| 5 years since November 17, 2021 | -25.2%-5.6% a yearPrice -25.2% | +149.9%+20.1% a yearPrice +115.7% |
| 10 years since November 18, 2016 | -52.5%-7.2% a yearPrice -52.5% | +308.8%+15.1% a yearPrice +205.6% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
AGIOAgios PharmaceuticalsAMGNAmgen
| Price | $29.68 | $443.89 |
|---|---|---|
| Market value | $1.7B | $239B |
| Enterprise value (EV) | $832M | $280B |
| P/E | – | 25.5 |
| P/E, 5-year median | – | 23.0 |
| P/B | 1.8 | 16.7 |
| EV/EBIT | – | 22.2 |
| Free cash flow yield | – | 4.0% |
| Revenue, 12 months | $141M | $38.9B |
|---|---|---|
| Net income, 12 months | -$373M | $9.4B |
| Free cash flow, 12 months | -$336M | $9.6B |
| Earnings per share, 12 months | -$6.32 | $17.25 |
| Revenue growth, year on year | 48.0% | 10.0% |
| Revenue growth a year, past | – | +7.6%over 5 years |
| EPS growth a year, past | – | +2.9%over 5 years |
| Gross margin | 93.8% | 70.9% |
|---|---|---|
| Operating margin | -297.7% | 32.4% |
| Net margin | -264.8% | 24.1% |
| ROIC | -29.6% | 16.2% |
| ROE | -33.3% | 87.8% |
| Cash | $907M | $13.2B |
|---|---|---|
| Total debt | $27M | $54.0B |
| Net debt / EBITDA | – | 2.3 |
| Interest cover | – | 4.8× |
| Dividend yield | – | 2.2% |
|---|---|---|
| Dividend per share, 12 months | – | $9.94 |
| Dividend growth a year, past | – | +8.1%over 5 years |
| Buyback yield | – | – |
| Shareholder yield | – | 2.2% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Amgen ($239B) is about 137.6 times Agios Pharmaceuticals ($1.7B), at today's prices.
Since November 18, 2016, AGIO's price moved -52.5% and AMGN's +205.6%. With dividends: AGIO -52.5% (-7.2% a year), AMGN +308.8% (+15.1% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Agios Pharmaceuticals and 2.24% for Amgen. Over the last twelve months they paid – and $9.94 per share.
Over the last twelve months, the net margin was -264.8% for Agios Pharmaceuticals and 24.1% for Amgen, and the operating margin -297.7% and 32.4%. Revenue was $141M and $38.9B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.